In conclusion, our data show that inhibition of Smad7 activates in CRC cells a program of cell death that is mediated by activation of PKR and support further the notion that Smad7 is a valid target for therapeutic strategies in CRC. The gene discussed is EIF2AK2; the disease is colorectal carcinoma.